Axiom Investors LLC DE Has $8.68 Million Stake in Lantheus Holdings, Inc. $LNTH

Key Points

• Axiom Investors LLC DE has reduced its stake in Lantheus Holdings, Inc. by 8.2%, owning 88,947 shares after selling 7,903 shares, which amounts to a total holding valued at approximately $8.68 million.
• Other institutional investors such as GAMMA Investing LLC and Assenagon Asset Management S.A. made significant increases in their holdings, with GAMMA growing its shares by 12,517.1% to own 128,442 shares valued at about $12.54 million.
• Lantheus recently reported earnings of $1.57 EPS, missing analyst estimates, and experienced a 4.1% decline in revenue compared to the same quarter last year.

Axiom Investors LLC DE lessened its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 8.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 88,947 shares of the medical equipment provider's stock after selling 7,903 shares during the quarter. Axiom Investors LLC DE owned 0.13% of Lantheus worth $8,681,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its stake in Lantheus by 3.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,084 shares of the medical equipment provider's stock valued at $1,162,000 after acquiring an additional 400 shares during the period. State of Alaska Department of Revenue grew its stake in shares of Lantheus by 2.7% in the 1st quarter. State of Alaska Department of Revenue now owns 8,142 shares of the medical equipment provider's stock valued at $794,000 after purchasing an additional 215 shares during the period. GAMMA Investing LLC grew its stake in shares of Lantheus by 12,517.1% in the 1st quarter. GAMMA Investing LLC now owns 128,442 shares of the medical equipment provider's stock valued at $12,536,000 after purchasing an additional 127,424 shares during the period. Cerity Partners LLC raised its holdings in shares of Lantheus by 12.7% in the 1st quarter. Cerity Partners LLC now owns 11,709 shares of the medical equipment provider's stock worth $1,143,000 after buying an additional 1,323 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in shares of Lantheus by 1,196.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider's stock worth $32,817,000 after buying an additional 310,301 shares during the period. 99.06% of the stock is owned by institutional investors.

Insider Buying and Selling at Lantheus

In other Lantheus news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rajiv A. Patel sold 3,365,000 shares of Lantheus stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,838,066 shares of company stock valued at $384,430,031. Company insiders own 1.50% of the company's stock.

Lantheus Trading Down 2.4%

NASDAQ LNTH traded down $1.34 on Thursday, reaching $55.50. The company had a trading volume of 1,062,154 shares, compared to its average volume of 1,206,632. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $118.21. The stock has a market cap of $3.77 billion, a price-to-earnings ratio of 14.76 and a beta of 0.14. The stock's 50 day moving average is $70.16 and its 200-day moving average is $83.58.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The firm had revenue of $378.05 million during the quarter, compared to analyst estimates of $389.69 million. During the same quarter in the prior year, the business earned $1.80 earnings per share. The business's revenue was down 4.1% on a year-over-year basis. Equities analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on LNTH shares. JMP Securities reduced their target price on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 7th. Truist Financial set a $63.00 price objective on Lantheus and gave the company a "hold" rating in a research report on Monday, August 11th. William Blair restated a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. Mizuho lowered their target price on Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th. Finally, Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $105.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.